XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.3
Acquisition and Equity-Method Investment - Pro Forma Information (Details) - Seagen [Member] - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 9 Months Ended
Oct. 01, 2023
Oct. 01, 2023
Business Acquisition [Line Items]    
Revenues $ 14,140 $ 46,756
Net income/(loss) attributable to Pfizer Inc. common shareholders $ (3,338) $ 2,702
Diluted earnings/(loss) per share attributable to Pfizer Inc. common shareholders $ (0.59) $ 0.47